Eton Pharmaceuticals, Inc. (ETON) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth No data.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth No data.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth No data.
30/50
3.0 / 5 stars
All 50 Win/Lose results and 70 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 7 wins, 1 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/2 |
WinETON / S&P 46.68% / 15.20% |
WinETON / S&P 81.49% / 15.00% |
No dataETON / S&P / 50.40% |
| 2026-Q12/2 |
WinETON / S&P 45.95% / -4.33% |
WinETON / S&P 79.89% / 11.30% |
No dataETON / S&P / 27.70% |
| 2025-Q41/2 |
LoseETON / S&P -22.18% / 2.65% |
WinETON / S&P 104.94% / 9.00% |
No dataETON / S&P / 13.40% |
| 2025-Q32/2 |
WinETON / S&P 52.49% / 8.12% |
WinETON / S&P 102.77% / 4.61% |
No dataETON / S&P / 13.45% |
| 2025-Q21/2 |
LoseETON / S&P 9.78% / 10.94% |
WinETON / S&P 85.40% / 4.83% |
No dataETON / S&P / 10.63% |
| 2025-Q12/2 |
WinETON / S&P -2.55% / -4.27% |
WinETON / S&P 40.88% / 4.98% |
No dataETON / S&P / 10.57% |
| 2024-Q42/2 |
WinETON / S&P 122.00% / 2.41% |
WinETON / S&P 23.29% / 5.25% |
No dataETON / S&P / 6.15% |
| 2024-Q31/2 |
WinETON / S&P 82.37% / 5.89% |
LoseETON / S&P 5.64% / 5.89% |
No dataETON / S&P / 6.11% |
| 2024-Q21/2 |
LoseETON / S&P -12.27% / 4.28% |
WinETON / S&P 8.14% / 5.38% |
No dataETON / S&P / 5.12% |
| 2024-Q11/2 |
LoseETON / S&P -14.38% / 10.56% |
WinETON / S&P 40.71% / 5.71% |
No dataETON / S&P / 5.59% |
| 2023-Q41/2 |
LoseETON / S&P 5.04% / 11.69% |
WinETON / S&P 48.90% / 6.81% |
No dataETON / S&P / 7.78% |
| 2023-Q32/2 |
WinETON / S&P 19.48% / -3.27% |
WinETON / S&P 74.19% / 7.52% |
No dataETON / S&P / -5.03% |
| 2023-Q21/2 |
LoseETON / S&P -9.35% / 8.74% |
WinETON / S&P 76.92% / 9.50% |
No dataETON / S&P / -8.57% |
| 2023-Q12/2 |
WinETON / S&P 36.52% / 7.50% |
WinETON / S&P 101.30% / 10.77% |
No dataETON / S&P / -15.69% |
| 2022-Q41/2 |
WinETON / S&P 34.29% / 7.56% |
LoseETON / S&P -2.66% / 11.88% |
No dataETON / S&P / -17.99% |
| 2022-Q31/2 |
LoseETON / S&P -19.85% / -4.88% |
WinETON / S&P 19.13% / 13.47% |
No dataETON / S&P / -1.41% |
| 2022-Q20/2 |
LoseETON / S&P -39.91% / -16.10% |
LoseETON / S&P 10.20% / 13.71% |
No dataETON / S&P / 11.04% |
| 2022-Q11/2 |
WinETON / S&P 1.63% / -4.60% |
LoseETON / S&P 2.31% / 15.97% |
No dataETON / S&P / 42.23% |
| 2021-Q41/2 |
LoseETON / S&P -14.88% / 11.03% |
WinETON / S&P 55879.49% / 15.00% |
No dataETON / S&P / 96.40% |
| 2021-Q31/2 |
LoseETON / S&P -18.18% / 0.58% |
WinETON / S&P 3693.76% / 10.77% |
No dataETON / S&P / 69.42% |
| 2021-Q20/1 |
LoseETON / S&P -15.85% / 8.55% |
No dataETON / S&P / 6.58% |
No dataETON / S&P / 51.81% |
| 2021-Q10/1 |
LoseETON / S&P -9.96% / 6.17% |
No dataETON / S&P / -1.06% |
No dataETON / S&P / 7.39% |
| 2020-Q40/1 |
LoseETON / S&P 2.91% / 12.15% |
No dataETON / S&P / -3.72% |
No dataETON / S&P / -33.42% |
| 2020-Q31/1 |
WinETON / S&P 44.95% / 8.93% |
No dataETON / S&P / -2.04% |
No dataETON / S&P / -27.10% |
| 2020-Q21/1 |
WinETON / S&P 32.93% / 20.54% |
No dataETON / S&P / -0.46% |
No dataETON / S&P / -27.11% |
| 2020-Q10/1 |
LoseETON / S&P -43.06% / -19.60% |
No dataETON / S&P / 3.47% |
No dataETON / S&P / -14.75% |
| 2019-Q41/1 |
WinETON / S&P 13.92% / 9.07% |
No dataETON / S&P / 5.36% |
No dataETON / S&P / 2.99% |
| 2019-Q30/1 |
LoseETON / S&P -20.00% / 1.70% |
No dataETON / S&P / 5.02% |
No dataETON / S&P / 0.21% |
| 2019-Q20/1 |
LoseETON / S&P -1.25% / 4.30% |
No dataETON / S&P / 6.64% |
No dataETON / S&P / 8.65% |
| 2019-Q11/1 |
WinETON / S&P 30.72% / 13.65% |
No dataETON / S&P / 8.12% |
No dataETON / S&P / 14.29% |
| 2018-Q40/0 |
No dataETON / S&P / -13.52% |
No dataETON / S&P / 9.05% |
No dataETON / S&P / 18.23% |
| 2018-Q30/0 |
No dataETON / S&P / 7.71% |
No dataETON / S&P / 10.21% |
No dataETON / S&P / 19.06% |
| 2018-Q20/0 |
No dataETON / S&P / 3.43% |
No dataETON / S&P / 9.03% |
No dataETON / S&P / 14.46% |
| 2018-Q10/0 |
No dataETON / S&P / -0.76% |
No dataETON / S&P / 7.68% |
No dataETON / S&P / 12.46% |
| 2017-Q40/0 |
No dataETON / S&P / 6.64% |
No dataETON / S&P / 7.03% |
No dataETON / S&P / 13.82% |
| 2017-Q30/0 |
No dataETON / S&P / 4.48% |
No dataETON / S&P / 5.68% |
No dataETON / S&P / 17.57% |
| 2017-Q20/0 |
No dataETON / S&P / 3.09% |
No dataETON / S&P / 4.83% |
No dataETON / S&P / 17.74% |
| 2017-Q10/0 |
No dataETON / S&P / 6.07% |
No dataETON / S&P / 3.67% |
No dataETON / S&P / 13.32% |
| 2016-Q40/0 |
No dataETON / S&P / 3.82% |
No dataETON / S&P / 2.09% |
No dataETON / S&P / 7.05% |
| 2016-Q30/0 |
No dataETON / S&P / 3.85% |
No dataETON / S&P / 0.20% |
No dataETON / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ETON total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 262.05% | 20.78% |
| Annualized return | 262.05% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ETON total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 1093.71% | 83.14% |
| Annualized return | 64.20% | 12.86% |
10Y · 2018-11-13 to 2026-08-27
| Metric | ETON total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 902.72% | 319.30% |
| Annualized return | 25.93% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |